FOXO4-DRI
Shop FOXO4-DRIAlso called: FOXO4 Compound, FOXO4-DRI UK, FOXO4 peptide
FOXO4-DRI is a special chemical made in a lab. It is a very small protein, or peptide, that scientists study to see how it affects cells. It is not a natural vitamin or a simple mineral. It is mostly used by researchers in labs to look at aging and health. It is not something you would find in a grocery store or take without a doctor's help.
The main reason scientists are interested in this peptide is because of how it interacts with old cells. In simple terms, our bodies have cells that stop working properly as we get older. These old cells can stick around and cause problems. FOXO4-DRI works like a key to unlock a door that lets these old cells shut down safely. This helps the body get rid of cells that are not doing their job anymore.
Right now, we do not know if this peptide is safe for people to use. Most of the research has been done on mice or in test tubes, not on humans. Because it is so new, there are many rules about who can buy it. It is sold only for research purposes, which means it is for studying in a lab and not for eating or injecting. Scientists are still trying to understand what it does and if it could be dangerous.
Benefits
What FOXO4-DRI Helps With
The benefits people report — backed by research.
Anti-aging & longevity (3)
More reported benefits (5)
Free: The Peptide Stack Cheat-Sheet
You just read the research on FOXO4-DRI. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Get FOXO4-DRI
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Evidence
Research Citations (10)
Every claim above traces back to a source you can check — here are 10 of them.
- Source
PubChem - Compound - Foxo4-dri
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
2020 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice.
2023 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.
2024 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
PubChem - Compound - FOXO4-DRI acetate
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Wondering how FOXO4-DRI pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →